Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 75.86% is in line with its 5-year average of 76.72%, around the middle of its 5-year range (74.07%–79.71%).
0.60% below its 12-month average of 76.32%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 74.07%.
GROSS MARGIN
75.86%
GROSS MARGIN AVG TTM
76.32%
GROSS MARGIN AVG 3Y
76.59%
GROSS MARGIN AVG 5Y
76.72%
GROSS MARGIN AVG 10Y
76.41%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.60%
CURRENT VS 3Y AVG
-0.95%
CURRENT VS 5Y AVG
-1.12%
CURRENT VS 10Y AVG
-0.72%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+83.33%
vs the sector median at left
IRadimed Corporation
Market Cap
$1.08B
Gross Margin
75.86%
TTM Avg
76.32%
3Y Avg
76.59%
5Y Avg
76.72%
Market Cap
$1.09B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.10B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.10B
Gross Margin
76.23%
TTM Avg
76.19%
3Y Avg
76.96%
5Y Avg
77.39%
Market Cap
$1.11B
Gross Margin
56.01%
TTM Avg
52.19%
3Y Avg
51.27%
5Y Avg
51.81%
Market Cap
$1.05B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$1.13B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IRadimed Corporation (IRMD) | $1.08B | 75.86% | 76.32% | 76.59% | 76.72% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| OPKO Health, Inc. (OPK)vs › | $1.09B | 21.10% | 32.36% | 32.56% | 33.45% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | 0.00% | 0.00% | 0.00% | 0.00% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 76.23% | 76.19% | 76.96% | 77.39% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | 56.01% | 52.19% | 51.27% | 51.81% |
| Replimune Group, Inc. (REPL)vs › | $1.11B | 0.00% | 0.00% | 0.00% | 0.00% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 73.53% | 70.13% | 70.04% | 68.74% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | 0.00% | 0.00% | 0.00% | 0.00% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 73.28% | 75.19% | 72.82% | 72.76% |
Gross Margin
75.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 74.07% |
| 2026-03-31 | 76.50% |
| 2025-12-31 | 75.06% |
| 2025-09-30 | 77.80% |
| 2025-06-30 | 78.17% |
| 2025-03-31 | 76.08% |
| 2024-12-31 | 76.13% |
| 2024-09-30 | 77.44% |
| 2024-06-30 | 78.14% |
| 2024-03-31 | 76.07% |
| 2023-12-31 | 76.86% |
| 2023-09-30 | 77.78% |
| 2023-06-30 | 75.55% |
| 2023-03-31 | 75.74% |
| 2022-12-31 | 75.49% |
| 2022-09-30 | 78.63% |
| 2022-06-30 | 79.71% |
| 2022-03-31 | 76.19% |
| 2021-12-31 | 77.91% |
| 2021-09-30 | 77.06% |
| 2021-06-30 | 74.74% |
| 2021-03-31 | 76.56% |
| 2020-12-31 | 75.35% |
| 2020-09-30 | 74.57% |
| 2020-06-30 | 72.56% |
| 2020-03-31 | 74.49% |
| 2019-12-31 | 74.82% |
| 2019-09-30 | 78.24% |
| 2019-06-30 | 79.86% |
| 2019-03-31 | 75.73% |
| 2018-12-31 | 76.23% |
| 2018-09-30 | 76.01% |
| 2018-06-30 | 76.81% |
| 2018-03-31 | 76.20% |
| 2017-12-31 | 75.54% |
| 2017-09-30 | 77.02% |
| 2017-06-30 | 77.66% |
| 2017-03-31 | 73.12% |
| 2016-12-31 | 78.23% |
| 2016-09-30 | 81.68% |
| 2016-06-30 | 82.38% |
| 2016-03-31 | 80.97% |
| 2015-12-31 | 82.95% |
| 2015-09-30 | 80.59% |
| 2015-06-30 | 81.31% |
| 2015-03-31 | 81.00% |
| 2014-12-31 | 74.36% |
| 2014-09-30 | 74.83% |
| 2014-06-30 | 81.50% |
| 2014-03-31 | 81.55% |
| 2013-12-31 | 72.55% |
| 2013-09-30 | 72.99% |
| 2013-06-30 | 72.33% |
| 2013-03-31 | 82.23% |
